[go: up one dir, main page]

MX2010001571A - Predictive markers for egfr inhibitor treatment. - Google Patents

Predictive markers for egfr inhibitor treatment.

Info

Publication number
MX2010001571A
MX2010001571A MX2010001571A MX2010001571A MX2010001571A MX 2010001571 A MX2010001571 A MX 2010001571A MX 2010001571 A MX2010001571 A MX 2010001571A MX 2010001571 A MX2010001571 A MX 2010001571A MX 2010001571 A MX2010001571 A MX 2010001571A
Authority
MX
Mexico
Prior art keywords
egfr inhibitor
inhibitor treatment
predictive markers
predictive
markers
Prior art date
Application number
MX2010001571A
Other languages
Spanish (es)
Inventor
Verena Lutz
Paul Delmar
Barbara Klughammer
Patricia Mcloughlin
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2010001571A publication Critical patent/MX2010001571A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention provides biomarkers which are predictive for the clinical benefit of EGFR inhibitor treatment in cancer patients.
MX2010001571A 2007-08-14 2008-08-07 Predictive markers for egfr inhibitor treatment. MX2010001571A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07114292 2007-08-14
PCT/EP2008/006513 WO2009021674A1 (en) 2007-08-14 2008-08-07 Predictive markers for egfr inhibitor treatment

Publications (1)

Publication Number Publication Date
MX2010001571A true MX2010001571A (en) 2010-03-15

Family

ID=39884813

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010001571A MX2010001571A (en) 2007-08-14 2008-08-07 Predictive markers for egfr inhibitor treatment.

Country Status (9)

Country Link
EP (1) EP2188391A1 (en)
JP (1) JP2010535517A (en)
KR (1) KR20100037637A (en)
CN (1) CN101778954A (en)
AU (1) AU2008286407A1 (en)
BR (1) BRPI0815415A2 (en)
CA (1) CA2695485A1 (en)
MX (1) MX2010001571A (en)
WO (1) WO2009021674A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2419522A4 (en) * 2009-04-17 2012-10-31 Glen Weiss METHODS AND KITS FOR PREDICTING THE THERAPEUTIC RESULT OF TYROSINE KINASE INHIBITORS
CN108732349A (en) * 2017-04-20 2018-11-02 中国科学院上海生命科学研究院 LTA4H is as tubercle and the biomarker of early warning liver cancer in instruction liver
CN108732350A (en) * 2017-04-20 2018-11-02 中国科学院上海生命科学研究院 PLA2G6 is as tubercle and the biomarker of early warning liver cancer in instruction liver
CN108732351A (en) * 2017-04-20 2018-11-02 中国科学院上海生命科学研究院 EPS8L2 is as tubercle and the biomarker of early warning liver cancer in instruction liver
CN110780072B (en) * 2019-12-09 2021-08-06 四川大学华西医院 Application of APOO autoantibody detection reagent in preparation of lung cancer screening kit

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5202231A (en) 1987-04-01 1993-04-13 Drmanac Radoje T Method of sequencing of genomes by hybridization of oligonucleotide probes
US5525464A (en) 1987-04-01 1996-06-11 Hyseq, Inc. Method of sequencing by hybridization of oligonucleotide probes
US5800992A (en) 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5795716A (en) 1994-10-21 1998-08-18 Chee; Mark S. Computer-aided visualization and analysis system for sequence evaluation
AU2001251613A1 (en) * 2000-04-14 2001-10-30 Millennum Pharmaceuticals, Inc. Novel genes, compositions and methods for the identification, assessment, prevention, and therapy of human cancers
AU2004211955B2 (en) * 2003-02-06 2009-05-14 Cedars-Sinai Medical Center Gene expression markers for response to EGFR inhibitor drugs
EP1633870B1 (en) * 2003-05-30 2013-03-27 OncoTherapy Science, Inc. Process for screening a drug response in cancer patients
DE602006016085D1 (en) 2005-03-16 2010-09-23 Genentech Inc BIOLOGICAL MARKERS PREDICTIVE FOR THE APPLICATION OF CANCER TO INHIBITORS OF THE CINEMA OF THE RECEPTOR FOR EPIDERMAL GROWTH FACTOR
AR053272A1 (en) * 2005-05-11 2007-04-25 Hoffmann La Roche DETERMINATION OF RESPONSIVES TO CHEMOTHERAPY
WO2007067500A2 (en) * 2005-12-05 2007-06-14 Genomic Health, Inc. Predictors of patient response to treatment with egfr inhibitors

Also Published As

Publication number Publication date
BRPI0815415A2 (en) 2015-02-03
AU2008286407A1 (en) 2009-02-19
CN101778954A (en) 2010-07-14
KR20100037637A (en) 2010-04-09
WO2009021674A1 (en) 2009-02-19
JP2010535517A (en) 2010-11-25
EP2188391A1 (en) 2010-05-26
CA2695485A1 (en) 2009-02-19

Similar Documents

Publication Publication Date Title
EA201171367A1 (en) VINYLINDASOLYL COMPOUNDS
WO2010017515A3 (en) Breast cancer specific markers and methods of use
MX2009012625A (en) Methods of treating, diagnosing and detecting fgf21-associated disorders.
IL182423A0 (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for cdk2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
MX2013002084A (en) Biomarkers and methods of treatment.
EA201270553A1 (en) BLUTON TYROSINKINASE INHIBITORS
WO2008008430A3 (en) Micro-rna-based methods and compositions for the diagnosis and treatment of colon cancer-related diseases
JO2788B1 (en) Amidophenoxyindazoles useful as inhibitors of c-met
EA200971068A1 (en) TRIAZOLYLAMINOPYRIMIDINE COMPOUNDS
WO2008104543A3 (en) Method for predicting the occurrence of metastasis in breast cancer patients
WO2009092108A3 (en) Biomarkers for the diagnosis and treatment of pancreatic cancer
MX2010001571A (en) Predictive markers for egfr inhibitor treatment.
WO2008054598A3 (en) Panel of biomarkers for prediction of fti efficacy
WO2010015538A3 (en) Predictive marker for egfr inhibitor treatment
MX343803B (en) Ipp complex as marker for erlotinib treatment.
EA200971067A1 (en) TRIAZOLYLAMINOPYRIMIDINE COMPOUNDS
EP2099458A4 (en) COMPOUNDS AND METHODS FOR IMAGING AND THERAPY OF ENZYME-MEDIATED TUMORS
MX2010001577A (en) Predictive marker for egfr inhibitor treatment.
MX2010001573A (en) Predictive marker for egfr inhibitor treatment.
MX2010001582A (en) Predictive markers for egfr inhibitors treatment.
MX2010001583A (en) Predictive marker for egfr inhibitor treatment.
MX2010001578A (en) Egfr inhibitor treatment marker.
MX2010001579A (en) Predictive marker for egfr inhibitor treatment.
MX2010001570A (en) Predictive marker for egfr inhibitor treatment.
TN2009000448A1 (en) Use of hdac inhibitors for the treatment of bone destruction

Legal Events

Date Code Title Description
FA Abandonment or withdrawal